^
Association details:
Biomarker:No biomarker
Cancer:Follicular Lymphoma
Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Initial palliative intent therapy for PTCL-NOS; EATL; MEITL and AITL, including Nodal PTCL, TFH, and FTCL and AITL….Ruxolitinib added as a category 2B, other recommended regimen for all subtypes.